3-methyl-5-isocyanato-isoquinoline | 581813-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 3-methyl-5-isocyanato-isoquinoline
• 英文别名: 5-isocyanato-3-methylisoquinoline
• CAS: 581813-01-6
• 化学式: C₁₁H₈N₂O
• 分子量: 184.197
• InChiKey: CVHZEQDQDMDUHT-UHFFFAOYSA-N

物化性质

• 沸点：
  302.8±27.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  42.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methyl-5-isocyanato-isoquinoline 、 3-氯苄胺 在 乙醚 作用下， 以 乙醚 为溶剂， 生成 N-(3-chlorobenzyl)-N'-(3-methyl-5-isoquinolinyl)urea
  参考文献：
  名称：

  Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

  摘要：

  式(I)1的化合物是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热痛敏、尿失禁和膀胱过度活动。

  公开号：

  US20040157849A1
• 作为产物：
  描述：

  3-甲基-5-硝基异喹啉 在 palladium on activated charcoal 4-二甲氨基吡啶 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 24.0h， 生成 3-methyl-5-isocyanato-isoquinoline
  参考文献：
  名称：

  In Vitro Structure−Activity Relationship and In Vivo Characterization of 1-(Aryl)-3-(4-(amino)benzyl)urea Transient Receptor Potential Vanilloid 1 Antagonists

  摘要：

  The synthesis and structure-activity relationship of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 (TRPV1) antagonists are described. A variety of cyclic amine substituents are well tolerated at the 4-position of the benzyl group on compounds containing either an isoquinoline or indazole heterocyclic core. These compounds are potent antagonists of capsaicin activation of the TRPV1 receptor in vitro. Analogues, such as compound 45, have been identified that have good in vivo activity in animal models of pain. Further optimization of 45 resulted in compound 58 with substantially improved microsome stability and oral bioavailability, as well as in vivo activity.

  DOI：

  10.1021/jm070276i

文献信息

• Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
  申请人：Gomtsyan Arthur

  公开号：US20060128689A1

  公开（公告）日：2006-06-15

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  对VR1受体拮抗剂，其化学式为(I)或其药用可接受的盐、前药或前药的盐，其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m的定义如本文所述，并且在通过抑制VR1受体预防或改善的疾病中具有用处。
• Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
  申请人：——

  公开号：US20040254188A1

  公开（公告）日：2004-12-16

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

  化合物式（I）1是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热痛觉增高、尿失禁或膀胱过度活动。
• [EN] FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES FUSIONNES QUI INHIBENT LE RECEPTEUR (VR1) SOUS-TYPE 1 DU RECEPTEUR VANILLOIDE
  申请人：ABBOTT LAB

  公开号：WO2004111009A1

  公开（公告）日：2004-12-23

  The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt or prodrug thereof (in which X1 - X5, R5 - R8b, Z1 - Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

  本发明揭示了一种新型化合物，其通式为(I)，或其药学上可接受的盐或前药（其中X1 - X5，R5 - R8b，Z1 - Z2和Ar1在此定义），一种使用这些化合物抑制哺乳动物中VR1受体的方法，一种控制哺乳动物疼痛的方法，以及包括这些化合物的制药组合物和制备这些化合物的方法。
• [EN] FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES AZABICYCLIQUES FUSIONNES QUI INHIBENT LE RECEPTEUR (VR1) SOUS-TYPE 1 DU RECEPTEUR VANILLOIDE
  申请人：ABBOTT LAB

  公开号：WO2003070247A1

  公开（公告）日：2003-08-28

  Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  化学式为(I)的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
• Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
  申请人：——

  公开号：US20040209884A1

  公开（公告）日：2004-10-21

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式(I)1的化合物是一种新型的VR1拮抗剂，可用于治疗疼痛、炎性热性过敏、尿失禁和膀胱过度活动。